No significant improvement seen in median time to resolution of symptoms with ivermectin versus placebo
IL-6 Receptor Antagonists Benefit Critically Ill With COVID-19
Improved outcomes, including more organ support-free days, reduced mortality, seen with tocilizumab, sarilumab
Combination Monoclonal Antibody Treatment Authorized for COVID-19
EUA issued for combination of bamlanivimab and etesevimab in patients with mild-to-moderate COVID-19 at high risk for disease progression
Peginterferon Lambda Accelerates SARS-CoV-2 Decline in Outpatients
After controlling for baseline viral load, patients receiving peginterferon lambda significantly more likely to have undetectable viral load
Small Study Tests Colchicine for Moderate-to-Severe COVID-19
Authors call for larger clinical trials to further evaluate the efficacy and safety of colchicine as an adjunctive therapy for COVID-19
Metformin Use for T2DM May Reduce COVID-19 Mortality
Odds of contracting COVID-19, COVID-19-related mortality higher for individuals with diabetes
Adverse Drug Reactions Linked to Hydroxychloroquine Up in 2020
ADRs associated with hydroxychloroquine, chloroquine more than doubled in 2020 versus 2018 and 2019
COVID-19 Outcomes No Worse for Patients on Immunosuppressive Meds
Findings for ventilator use, length of stay, in-hospital mortality similar for those with, without chronic use of immunosuppressant agents
No Evidence Found to Support Discontinuing ACEIs, ARBs in COVID-19
Mean number of days alive and out of hospital not significantly different for those discontinuing, continuing meds
Bamlanivimab + Etesevimab Reduces SARS-CoV-2 Viral Load
No significant reduction seen in viral load at day 11 with bamlanivimab monotherapy in mild-to-moderate COVID-19